Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Initiation of Phase 2 Study of Recombinant Human Beta-Glucuronidase in Patients Under Five Years Old With Mucopolysaccharidosis 7

Wednesday, August 5, 2015 1 min read
Key Takeaway: Ultragenyx Announces Initiation of Phase 2 Study of Recombinant Human Beta-Glucuronidase in Patients Under Five Years Old With Mucopolysaccharidosis 7

Full Press Release Details

Ultragenyx Announces Initiation of Phase 2 Study of Recombinant Human Beta-Glucuronidase in Patients Under Five Years Old With Mucopolysaccharidosis 7.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 5, 2015